Navigate the fast-moving cannabis sector with 420 Investor, a premium service that sends real-time alerts and explanations of the news below and much more.
- Financial reports continued to point to a slowing of capital spending during Q3 and Q4.
- Health Canada added 7 new licenses, leaving the total now at 791.
- 420 Investor model portfolios have gained 1.3-37.7% year-to-date, while the Global Cannabis Stock Index has lost 7.5%.
A pre-announcement by Hydrofarm and a short-fall by Gibraltar Industries pointed to slowing capital equipment sales.
Health Canada added 4 licenses, leaving the total at 784, including 12 that are expired, revoked or suspended.
During the week, I shared these insights with subscribers at 420 Investor:
- Model Portfolio Composition 10/22/21
- Cannabis Sub-Sector Review – 10/22/21
- A First Look at 2022 MSO Expected Financials
- Previews of Upcoming Financial Reports for Scotts Miracle-Gro and Canopy Growth
Here are some of this week’s highlights for 420 Investor Focus List names:
- CCHWF announced a CBD line with Pitbull and a THC line with Mike Tyson. It began offering whole flower in New York.
- CGC introduced new Martha Stewart CBD offerings
- CRLBF opened 2 medical cannabis dispensaries in Florida, giving them 11 in the state
- CRON announced the retirement of its Chief Innovation Officer
- CURLF began selling whole flower in New York
- CWBHF introduced pet chews for dogs with sensitive skin
- FFLWF announced the departure of its COO as it streamlined senior management. The company paid down C$2.3 million in debt on its ATB Financial credit line.
- GRAMF introduced DELI Dimes, three flavors of affordable gummies
- TCNNF rebranded another three Harvest dispensaries in Florida and two new ones to give them 107 currently in operation
- TLRY was named by Luxembourg as a medical cannabis supplier
- VFF announced that its CBD subsidiary Balanced Health Botanicals has begun offering products that include other cannabinoids and non-cannabis compounds.
- VRNOF opened a dispensary with a drive-through on Flamingo Road in Las Vegas, its third in the city
The Global Cannabis Stock Index posted a new 2021 closing to end the month, decreasing 3.2% to 41.06:
The index, which lost 34.1% in 2019 and lost 54.9% in 2018 after gaining 91.8% in 2017 and 88.8% in 2016, was up 5.2% in 2020. It has lost 7.5% in 2021 thus far. It currently includes 42 stocks and ended 2020 at 44.39:
420 Investor offers three model portfolios for subscribers, including two that are long-term focused and fully invested with a goal of beating the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week valued at $117,542, down 5.3%. The model portfolio, up 11.6% in 2021, gained 35.6% in 2020 and has increased 135.1% since April 2014 despite the large loss in the index since then. 420 Quality ended the week at $163,585, down 5.4% for the week, and is now up 1.3% in 2021 after gaining 42.8% in 2020. The model was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 227.2% since inception compared to the 49.2% decline in the index since then. Flying High, which is focused on swing trades, ended the week valued at $347,591, down 5.0%. The model portfolio gained 52.7% in 2020 and is up 37.7% in 2021, and the return since inception in late 2013 has been 3376%.
After a strong rally to begin 2019, the cannabis sector experienced a sharp decline over the next year to unprecedented levels due to several negative developments, including the CannTrust fraud, the surprise termination of Bruce Linton as CEO of Canopy Growth, a disappointing roll-out of legalization in Canada, regulatory confusion in the U.S. regarding CBD and a slow roll-out of legalization in California, the vaping crisis and then financial turmoil and market disruptions due to the COVID-19 pandemic. The sector saw capital available to fund expansion dry up, a situation that continues to leave companies operating with negative cash flow severely challenged, as the availability is limited to stronger operators.
Cannabis stocks overreacted and put in a bottom in March 2020, and benefited from a perception that the industry offers strong growth prospects, something that wasn’t clear then. A big change was that the pandemic caused many regulators to permit previously prohibited types of retail activities, like curbside pickup and delivery. The legal market rapidly capitalized on becoming even more convenient than the illicit market, with the ability to order online. States and municipalities moved to broaden adult-use and medical access. Access to capital improved dramatically, and the leading companies began generating large and rapidly growing revenue and profits.
The strong finish to 2020 continued into 2021 after the Democrats took control of the Senate in early January, but the stocks got way ahead of themselves and have been consolidating since then. In addition to concerns that federal legalization will take a longer time than many have expected, there have been some tough comparisons to year-ago sales levels. Additionally, while several institutions embraced the sector early in the year, there has been a lull in additional interest.
There are several potential catalysts ahead, including the FDA (or Congress) providing clarity on CBD regulation, progress in the Canadian legalization that commenced in October 2018 and that is beginning to include a broader set of products and the continued growth in German and Israeli MMJ and other international markets that have been slow to develop. The adult-use implementations in California and Massachusetts for adult-use were slow to roll out but are beginning to show great improvement. Michigan and Illinois legalized for adult-use at the end of 2019, and these markets are showing strong growth that could encourage other states to legalize. Voters in Arizona, Montana, South Dakota and New Jersey all approved adult-use legalization in November, and Connecticut, New Mexico, New York and Virginia have enacted legalization through the legislative process in 2021.
The big themes ahead are likely to be continued cross-industry investment into the sector and more consolidation in Canada and in the U.S., potential federal regulatory reform (SAFE Banking Act and other more comprehensive legislation, which could eliminate 280E taxation and enable trading on higher exchanges for MSOs as well as the broad usage of credit cards for cannabis purchases), steps to enable cannabis research, the roll out of MMJ in Germany, Mexico and in Australia as well as continued advances in South America and potential adult-use legalization in Israel and Mexico, new legal cannabis implementations in AZ, MT, NJ and SD, and MMJ implementations in AL, WV and VA, possible legalization via the legislatures in DE, FL, MD, MN, NH, PA and RI and implementation of the CT, NM, NY and VT commercial programs in 2022 and VA in 2024.
After bottoming in March 2020, the cannabis sector has been in a new bull market. Many companies are generating substantial revenue and some even a profit, and liquidity is much better. The sector has transitioned away from many legacy penny stocks that had never proven that they had viable businesses towards better capitalized companies, many of which have strong management teams and substantial businesses. The investor base has also transitioned, becoming increasingly more institutional.